Press release, Stockholm 12 June 2019 (Swedish version)
Report from extraordinary general meeting of Bio-Works Technologies AB on 12 June 2019
Today, 12 June 2019, an extraordinary general meeting was held in Bio-Works Technologies AB. At the meeting, a decision was made to approve the board of director’s resolution on a directed new issue of a maximum of 5,555,600 shares, which means an increase of the share capital by a maximum of SEK 555,560.
The right to subscribe for the new shares shall, with deviation from the shareholders’ pre-emptive right, vest in Northal Investment AB, Thomas Eklund, Newton Aguiar, Amicogen Inc., Färjsundet Industri Aktiebolag and Rhenman Healthcare Equity L / S. The subscription price in the issue is SEK 6.30 per share and subscription of the shares shall be made by cash payment.
The reason for the deviation from the shareholders’ pre-emptive rights is to approach institutional investors and at the same time quickly secure financing for further development of the business. The basis for the subscription price is an agreement between the subscribers and is based on the share’s market price.
For more information, please contact:
Mats Johnson, CEO
Tel: +46 70 516 53 37
This information was provided by the person named above for publication in Swedish at 11:30 CET on 12 June 2019.
Bio-Works is a biotechnology company that develops, produces and sells innovative separation media products based on agarose to purify proteins, peptides and other biomolecules. The company’s products are mainly used for purifying biological drugs and diagnostic products, from the research phase to large-scale production. The products are sold globally partly through its own organization and partly through distributors. The Bio-Works facility is located in Uppsala Business Park in Uppsala, Sweden. The company’s share is listed on Nasdaq First North. FNCA Sweden AB, +46 (0) 8-528 00 399, email@example.com, is appointed Certified Adviser.